A Phase I/II and Target Validation Study of TAK-580 (MLN2480) for Children With Low-Grade Gliomas and Other RAS/RAF/MEK/ERK Pathway Activated Tumors

Trial Profile

A Phase I/II and Target Validation Study of TAK-580 (MLN2480) for Children With Low-Grade Gliomas and Other RAS/RAF/MEK/ERK Pathway Activated Tumors

Not yet recruiting
Phase of Trial: Phase I/II

Latest Information Update: 16 Feb 2018

At a glance

  • Drugs TAK 580 (Primary)
  • Indications CNS cancer; Glioma; Solid tumours
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 14 Feb 2018 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top